Camp4 Therapeutics Inc 5.10 +0.58(+12.83%) 1日 1周 1个月 3个月 6个月 1年 5年 最大值 CAMP评分 公司稳健度解锁 公允价值解锁价格 公允价格 看涨 技术分析 买入 分析师观点 强力买入 目标价 19.91 看涨 +290.34% 成员看法 看空 看多 ProTips 解锁全部13条Tips 烧钱速度快 ...
CAMP4 Therapeutics Corporation announced positive safety results from its clinical trial for CMP-CPS-001, targeting urea cycle disorders (UCDs), and completed the first two cohorts of its Multiple Ascending Dose (MAD) study while entering the third cohort. The company expects to rep...
Camp4 Therapeutics所有资讯 新闻 公告 评级 CAMP4将参加即将举行的投资者会议 马萨诸塞州剑桥,2025年2月6日( globe 新闻网)-- CAMP4 Therapeutics Corporation("CAMP4")(纳斯达克:CAMP),一家临床阶段的生物技术公司,正在开发一系列针对regRNA的治疗药物。 GlobeNewswire02/06 21:00 CAMP4将在第43届摩根大通医疗...
Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Sector Health Care Industry Biotechnology Employees 53 Founded 2015...
周二,Piper Sandler开始对CAMP4 Therapeutics Corp (NASDAQ:CAMP)股票进行覆盖,给予超配评级,目标价为18.00美元。该公司强调了CAMP4在开发调节性RNA(regRNAs)作为新治疗方法方面的创新工作。 据Piper Sandler称,CAMP4的RNA激活平台在设计针对regRNAs的反义寡核苷酸以增强基因表达和治疗遗传疾病方面处于领先地位。
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein le...
Pause Main Menu
camp4 therapeutics corp. u.s.: nasdaq 0.00 camp delayed quote about camp4 therapeutics corp. camp4 therapeutics corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. the company was founded by richard a. young and leonard zon in 2015 ...
CAMP4 Therapeutics Corp. +Watchlist You must be logged in to create alerts After Hours Last Updated:Feb 21, 2025 4:05 p.m.ESTDelayed quote $4.8100 0.000.00% After Hours Volume:721 CloseChgChg % $4.8100-0.0200-0.41% Toggle Chart Options ...
OPKO Health, Inc., a multinational biopharmaceutical and diagnostics company, announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation (CAMP4) for the development, manufacture and commercialization of therapeutics utilizing the AntagoNAT technology, an...